Literature DB >> 28790148

The Actions of Drug Combinations on the GABAA Receptor Manifest as Curvilinear Isoboles of Additivity.

Daniel J Shin1, Allison L Germann1, Joe Henry Steinbach1, Gustav Akk2.   

Abstract

Drug interactions are often analyzed in terms of isobolograms. In the isobologram, the line connecting the axial points corresponding to the concentrations of two different drugs that produce an effect of the same magnitude is termed an isobole of additivity. Although the isobole of additivity can be a straight line in some special cases, previous work has proposed that it is curvilinear when the two drugs differ in their maximal effects or Hill slopes. Modulators of transmitter-gated ion channels have a wide range of maximal effects as well as Hill slopes, suggesting that the isoboles for drug actions on ion channel function are not linear. In this study, we have conducted an analysis of direct activation and potentiation of the human α1β2γ2L GABAA receptor to demonstrate that: 1) curvilinear isoboles of additivity are predicted by a concerted transition model where the binding of each GABAergic drug additively and independently reduces the free energy of the open receptor compared with the closed receptor; and 2) experimental data for receptor activation using the agonist pair of GABA and propofol or potentiation of responses to a low concentration of GABA by the drug pair of alfaxalone and propofol agree very well with predictions. The approach assuming independent energetic contributions from GABAergic drugs enables, at least for the drug combinations tested, a straightforward method to accurately predict functional responses to any combination of concentrations.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28790148      PMCID: PMC5635521          DOI: 10.1124/mol.117.109595

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  34 in total

1.  Response surface model for anesthetic drug interactions.

Authors:  C F Minto; T W Schnider; T G Short; K M Gregg; A Gentilini; S L Shafer
Journal:  Anesthesiology       Date:  2000-06       Impact factor: 7.892

2.  The problem of synergism and antagonism of combined drugs.

Authors:  S LOEWE
Journal:  Arzneimittelforschung       Date:  1953-06

3.  Occupation of either site for the neurosteroid allopregnanolone potentiates the opening of the GABAA receptor induced from either transmitter binding site.

Authors:  John Bracamontes; Megan McCollum; Caroline Esch; Ping Li; Jason Ann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

4.  On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine.

Authors:  A Karlin
Journal:  J Theor Biol       Date:  1967-08       Impact factor: 2.691

Review 5.  Monod-Wyman-Changeux allosteric mechanisms of action and the pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Curr Opin Anaesthesiol       Date:  2012-08       Impact factor: 2.706

6.  Modes and models of GABA(A) receptor gating.

Authors:  Gareth M C Lema; Anthony Auerbach
Journal:  J Physiol       Date:  2006-02-02       Impact factor: 5.182

7.  Barbiturate-benzodiazepine interactions at the gamma-aminobutyric acidA receptor in rat cerebral cortical synaptoneurosomes.

Authors:  T M DeLorey; I Kissin; P Brown; G B Brown
Journal:  Anesth Analg       Date:  1993-09       Impact factor: 5.108

8.  A propofol binding site on mammalian GABAA receptors identified by photolabeling.

Authors:  Grace M S Yip; Zi-Wei Chen; Christopher J Edge; Edward H Smith; Robert Dickinson; Erhard Hohenester; R Reid Townsend; Karoline Fuchs; Werner Sieghart; Alex S Evers; Nicholas P Franks
Journal:  Nat Chem Biol       Date:  2013-09-22       Impact factor: 15.040

9.  Altered Channel Conductance States and Gating of GABAA Receptors by a Pore Mutation Linked to Dravet Syndrome.

Authors:  Ciria C Hernandez; Weijing Kong; Ningning Hu; Yujia Zhang; Wangzhen Shen; Laurel Jackson; Xiaoyan Liu; Yuwu Jiang; Robert L Macdonald
Journal:  eNeuro       Date:  2017-02-10

10.  Correction for Inhibition Leads to an Allosteric Co-Agonist Model for Pentobarbital Modulation and Activation of α1β3γ2L GABAA Receptors.

Authors:  Alexis M Ziemba; Stuart A Forman
Journal:  PLoS One       Date:  2016-04-25       Impact factor: 3.240

View more
  16 in total

1.  Binding site location on GABAA receptors determines whether mixtures of intravenous general anaesthetics interact synergistically or additively in vivo.

Authors:  Daniel E Kent; Pavel Y Savechenkov; Karol S Bruzik; Keith W Miller
Journal:  Br J Pharmacol       Date:  2019-12-11       Impact factor: 8.739

2.  Analysis of GABAA Receptor Activation by Combinations of Agonists Acting at the Same or Distinct Binding Sites.

Authors:  Daniel J Shin; Allison L Germann; Douglas F Covey; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-18       Impact factor: 4.436

Review 3.  Applying the Monod-Wyman-Changeux Allosteric Activation Model to Pseudo-Steady-State Responses from GABAA Receptors.

Authors:  Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-10-17       Impact factor: 4.436

4.  Reduced Activation of the Synaptic-Type GABAA Receptor Following Prolonged Exposure to Low Concentrations of Agonists: Relationship between Tonic Activity and Desensitization.

Authors:  Spencer R Pierce; Allison L Germann; Alex S Evers; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2020-09-25       Impact factor: 4.436

5.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

6.  High Constitutive Activity Accounts for the Combination of Enhanced Direct Activation and Reduced Potentiation in Mutated GABAA Receptors.

Authors:  Allison L Germann; Daniel J Shin; Christina R Kuhrau; Alexander D Johnson; Alex S Evers; Gustav Akk
Journal:  Mol Pharmacol       Date:  2018-02-08       Impact factor: 4.436

7.  Monod-Wyman-Changeux Allosteric Shift Analysis in Mutant α1β3γ2L GABAA Receptors Indicates Selectivity and Crosstalk among Intersubunit Transmembrane Anesthetic Sites.

Authors:  Andrea Szabo; Anahita Nourmahnad; Elizabeth Halpin; Stuart A Forman
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

8.  Steady-State Activation and Modulation of the Concatemeric α1β2γ2L GABAA Receptor.

Authors:  Allison L Germann; Spencer R Pierce; Ariel B Burbridge; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2019-07-01       Impact factor: 4.436

9.  The Sulfated Steroids Pregnenolone Sulfate and Dehydroepiandrosterone Sulfate Inhibit the α1β3γ2L GABAA Receptor by Stabilizing a Novel Nonconducting State.

Authors:  Spencer R Pierce; Allison L Germann; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2021-12-01       Impact factor: 4.436

10.  Intrasubunit and Intersubunit Steroid Binding Sites Independently and Additively Mediate α1β2γ2L GABAA Receptor Potentiation by the Endogenous Neurosteroid Allopregnanolone.

Authors:  Allison L Germann; Spencer R Pierce; Hiroki Tateiwa; Yusuke Sugasawa; David E Reichert; Alex S Evers; Joe Henry Steinbach; Gustav Akk
Journal:  Mol Pharmacol       Date:  2021-05-06       Impact factor: 4.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.